Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Not yet recruiting 1Active not recruiting 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2Sarcoma 2Gynecologic 2Genitourinary 2Gastrointestinal 2Dermatologic 2Lymphoid 1Head & Neck 1Breast 1

Conditions

Lung Neoplasms 51Leukemia, Myeloid, Acute 45Neoplasm Metastasis 43Carcinoma, Non-Small-Cell Lung 37Breast Neoplasms 37Prostatic Neoplasms 30Multiple Myeloma 30Colorectal Neoplasms 27Pancreatic Neoplasms 26Melanoma 23Carcinoma, Renal Cell 23Ovarian Neoplasms 21Lymphoma 20Burkitt Lymphoma 19Triple Negative Breast Neoplasms 18Myelodysplastic Syndromes 18Leukemia, Lymphocytic, Chronic, B-Cell 18Lymphoma, Large B-Cell, Diffuse 17Urinary Bladder Neoplasms 16Precursor Cell Lymphoblastic Leukemia-Lymphoma 16Squamous Cell Carcinoma of Head and Neck 14Glioblastoma 14Fallopian Tube Neoplasms 14Carcinoma, Hepatocellular 14Oropharyngeal Neoplasms 13Glioma 13Sarcoma 12Mouth Neoplasms 12Carcinoma 12Astrocytoma 12

Interventions

Nivolumab 4pomalidomide 2Specimen Handling 2Magnetic Resonance Spectroscopy 2liposomal doxorubicin 1cabozantinib 1abemaciclib 1Propranolol 1Everolimus 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Sarcoma, Kaposi × Specimen Handling × 90 days × Clear all
NCT04514484 2026-05-28

Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV

National Cancer Institute (NCI)

Phase 1 Active not recruiting
8 enrolled 32 charts
BreastDermatologicGastrointestinalGenitourinaryGynecologicSarcomaThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Carcinoma, Hepatocellular, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Ovarian Neoplasms, Prostatic Neoplasms, Sarcoma, Kaposi, HIV Infections, Carcinoma, Medullary, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT07576725 2026-05-08

Low Dose, Reduced Frequency Nivolumab for the Treatment of Unresectable or Metastatic Cancer, AFFORD IO Trial

Fred Hutchinson Cancer Center

Phase 2 Not yet recruiting
50 enrolled
DermatologicGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidSarcomaThoracic

Clear-cell metastatic renal cell carcinoma, Squamous Cell Carcinoma of Head and Neck, Carcinoma, Basal Cell, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Hodgkin Disease, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Sarcoma, Kaposi, Colorectal Neoplasms, Carcinoma, Merkel Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡